PCK
PAINCHEK LTD
$0.0860
▼ -13.13%
Market cap
$18M
Turnover
$333,341
Last price
$0.0860
Day change
-13.13%
Announcements
9
Range, past year
Open 0.060 · Low 0.033 · Now 0.086 · High 0.350
Open PCK in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
PCK momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
22/100
Wyckoff phase
Downtrend16d
Trend stage
Breakdown
1 Day
-13.1%
1 Week
-10.4%
1 Month
-25.2%
1 Year
-84.2%
RSI
29
Avg daily range
7.9%
PAINCHEK LTD scores 22 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 16 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- RSI oversold (29)
- 60d drawdown -31.2%
- High volatility (ATR 7.9%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsPCK announcements
Recent price-sensitive releases.
- 2026-10-13 PainChek expands Sabra contracts to 23 US communities Progress Report
- 2026-08-28 Appendix 4E and Financial Report Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report | Notice of Meeting - Other
- 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-22 PainChek receives $1.123 million R&D tax incentive refund
- 2026-07-20 US MedTech leader Karen Holzberger appointed CEO
- 2026-05-22 PainChek secures A$5.5m note to fund US expansion
- 2026-04-30 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.